Clinical Trial Update: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer [Phase 1]

View source ↗

Summary

The Phase 1 study of KHK2866, an HB-EGF–targeting antibody, in advanced solid tumors and ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• KHK2866 (HB-EGF–targeting monoclonal antibody)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Neoplasms, Ovarian Neoplasms | Phase 1 | Status: TERMINATED